MTUS1 and neoplasm: Furthermore, ATIP3 re-expression lowers the incidence, time-course and size of tumor progression in xenograft models in vivo, suggesting that ATIP3 may represent an interesting candidate for future targeted therapies of triple negative breast tumors.